

10/525964 13

CTSD Rec'd PCT/PTO 2 8 FEB 2005


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Hiroshi TERADA, et al.**Serial Number: **Not Yet Assigned**
(§371 of International Application PCT/JP03/10871)Filed: **February 28, 2005**For: **REMEDY****INFORMATION DISCLOSURE STATEMENT**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

February 28, 2005

Sir:

In compliance with 37 CFR 1.56, Applicants call to the attention of the Patent and

Trademark Office the references listed on the attached PTO-1449 which are cited in the enclosed
international search report.In the event there are any fees due in connection with the filing of this paper, please
charge Deposit Account No. 01-2340.Respectfully submitted,
ARMSTRONG, KRATZ, QUINTOS,
HANSON & BROOKS, LLP
James E. Armstrong, IV
Attorney for Applicants
Reg. No. 42,266JAM/jaz
Atty. Docket No. 050106
Suite 1000
1725 K Street, N.W.
Washington, D.C. 20006
(202) 659-2930

23850

PATENT TRADEMARK OFFICE

Enclosures: PTO-1449; International Search Report

INFORMATION DISCLOSURE STATEMENT PTO-1449	Atty. Docket No. 050106	Serial No. New Application
	Applicant(s): Hiroshi TERADA, et al.	
	Filing Date: February 28, 2005	Group Art Unit: Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Name	Date	Class	Subclass	Filing Date (If appropriate)
_____	AA					
_____	AB					
_____	AC					
_____	AD					

FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Translation (Yes or No)
_____ AE	2000-186040	07/04/00	Japan
_____ AF	11-116498	04/27/99	Japan

OTHER DOCUMENTS

_____	AG	P. O'Hara, et al; "Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization;" <i>Pharm. Res.</i> ; Vol. 17; No. 8; 2000; pp. 955-961./Discussed in the specification.
_____	AH	R. Sharma, et al.; "Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis;" <i>Pharm. Res.</i> ; Vol 18; No. 10; 2001; pp. 1405-1410./Discussed in the specification.
_____	AI	E.L. Barrow, et al; "Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages;" <i>Antimicrobial Agents and Chemotherapy</i> ; Vol. 42; No. 10; 1998; pp. 2682-2689.
Examiner	/Paul Dickinson/	
Date Considered	02/27/2008	